Daily Roundup

Ramelius Resources stays on track with solid quarter despite weather headwinds

Gold miner Ramelius Resources delivered 48,839 ounces of gold in the September quarter at an all-in sustaining cost of A$2,656 per ounce. While weather interruptions affected operations and built up stockpiles, the company maintained momentum with operating cash flow of A$186 million and boosted its cash and gold position to A$768 million following the completion of its Edna May asset sale for A$300 million.

The divestment saw Ramelius receive A$210 million in cash and A$90 million in Forrestania shares, providing a war chest for growth initiatives. The company remains firmly on track to hit its full-year guidance of 205,000 to 225,000 ounces at an AISC of A$2,150 to A$2,350 per ounce. Beyond the current year, Ramelius is systematically derisking its business plan with the goal of becoming a 600,000 ounce producer by FY30. Key milestones this quarter included the award of an EPC contract for the Mt Magnet plant upgrade and EPA approval for the Roe site, while exploration activities continued with 39,559 metres of drilling completed.

Pureprofile accelerates with record revenue and surging platform growth

Data insights company Pureprofile is firing on all cylinders, posting record quarterly revenue of $18.3 million, up 14% from the prior year. More impressively, EBITDA jumped 27% to $2.4 million, showing the company is converting growth into profitability faster than revenue is climbing. The standout performer was platform revenue, which more than doubled to $8.8 million and now represents 48% of total revenue.

The ANZ region led the charge with 21% revenue growth to $9.6 million, while the rest of the world grew 7% to $8.7 million. Pureprofile now works with over 1,000 clients globally, and rolling 12-month annuity revenue reached $16.9 million. The company also secured improved commercial terms on its $2.5 million Commonwealth Bank facility, extending it through November 2029. For the full year, Pureprofile is guiding for revenue between $72 million and $75 million with an EBITDA margin of 11% to 12%.

Artrya makes waves in U.S. market with major hospital deal

Medical technology company Artrya is gaining serious traction in the United States with a five-year commercial agreement signed with Huntsville Hospital Health System, its largest customer to date. The hospital also became the first participant in Artrya's SAPPHIRE study to convert to full commercial use of the company's Salix® platform.

The quarter also saw material progress at Tanner Health, where the implementation of a pre-authorization workflow led to a significant uptick in Salix® Coronary Plaque utilization. On the governance front, Artrya strengthened its Board and executive leadership team, and the company was included in the S&P/ASX 300 Index, a recognition of its growing stature. The company plans to continue expanding U.S. operations with a focus on processing more coronary CT angiography studies through Salix® and driving adoption of its Coronary Plaque module.

Mach7 Technologies hits historic milestone with positive cash flow

Medical imaging software company Mach7 Technologies has achieved its first positive operating cash flow in company history, posting A$0.3 million for the quarter. Even more significant, this marks the fourth consecutive quarter of positive cash generation, signaling a fundamental shift in the business trajectory.

The company's Annual Recurring Revenue run rate climbed to A$23.5 million, up 8.5% in constant currency year-on-year, driven by growth in its installed base and new customer wins. Receipts surged 58% compared to the prior year, reflecting both customer expansion and improved cash collection practices. Mach7 maintains a fortress balance sheet with A$19.3 million in cash and zero debt, providing ample firepower for innovation and growth. The company is preparing to unveil its next-generation Flamingo architecture at RSNA 2026, representing a modular platform designed to expand its addressable market and attract early adopters.

Invex charts new course with Rekover acquisition and capital raise

Biotech company Invex Therapeutics is reshaping its portfolio through the acquisition of Rekover Therapeutics, a New Zealand-based biotech firm focused on repurposing nalfurafine for demyelinating diseases. The all-scrip deal will see Invex issue 45 million shares and 91.25 million performance rights, with no cash changing hands upfront. Performance rights will vest upon achieving specific milestones, aligning incentives with execution.

To fund the REVIVE Study and develop its existing Exenatide assets, Invex is raising $10 million through a placement. An initial 11.25 million shares at $0.08 each is already committed, with an additional 113.75 million shares planned subject to shareholder approval. The transaction itself also requires shareholder sign-off, with the capital raise expected to accelerate the company's clinical and commercial momentum.